IGM Biosciences Accounts Payable

IGM Biosciences (IGMS) currently reports a accounts payable of $2.4M as of June 2025. That compares with $3.3M in the prior-year period — down 26.4% year over year. Use the charts on this page to explore IGM Biosciences's accounts payable history and peer comparisons.

IGM Biosciences's accounts payable decreased from $3.3M to $2.4M — a 26.4% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IGM Biosciences reported $2.4M in accounts payable as of June 2025. That compares with $3.3M in the prior-year period — down 26.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for IGM Biosciences, and consider following IGMS for alerts when major investors trade the stock.

IGM Biosciences is classified in the Healthcare sector. On accounts payable, it currently shows $2.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IGMS with unrelated industries.